LAG3 and cancer: In recent years, with the discovery of the considerable therapeutic potential of cancer immunotherapy, researchers have developed new immune checkpoint targets, such as TIM3, lymphocyte activation gene 3 (LAG3), and tyrosine-based inhibition motif domain (TIGIT) [9].